New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing]

LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing]

Treatment Overview

Cycle 1 (and all further cycles) - 14 days

Cycle length:
14

Cycle details

Cycle 1 (and all further cycles) - 14 days

Medication Dose Route Days Max Duration
nivolumab 240 mg flat dosing intravenous 1 30 minutes

Full details

Cycle 1 (and all further cycles) - 14 days

Day: 1

Medication Dose Route Max duration Details
nivolumab 240 mg flat dosing intravenous 30 minutes
Instructions:
Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 1.2 micron in-line filter.

Supportive Care Factors

Factor Value
Emetogenicity: Minimal

References

1. Long, G. V., S. S. Tykodi, J. G. Schneider, et al. 2018. "Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer." Ann Oncol 29(11):2208-2213., PMID: 30215677

2. Zhao, X., S. Suryawanshi, M. Hruska, et al. 2017. "Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors." Ann Oncol 28(8):2002-2008., PMID: 28520840

3. Brahmer, J., K. L. Reckamp, P. Baas, et al. 2015. "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer." N Engl J Med 373(2):123-135., PMID: 26028407

4. Borghaei, H., L. Paz-Ares, L. Horn, et al. 2015. "Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer." N Engl J Med 373(17):1627-1639., PMID: 26412456

5. Horn, L., D. R. Spigel, E. E. Vokes, et al 2017. "Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)." J Clin Oncol 35(35):3924-3933., PMID: 29023213

6. Vokes, E. E., N. Ready, E. Felip et al. 2018. "Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases." Ann Oncol 29(4):959-965., PMID: 29408986

7. Bristol-Myers Squibb (NZ) Limited. Opdivo New Zealand Data Sheet 20 May 2020. https://www.medsafe.govt.nz/profs/Datasheet/o/opdivoinf.pdf (Accessed 02 December 2020)

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.